Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Chemotherapy in HR+/HER2- Breast Cancer (PANKU-Breast03)
NCT07648914Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in breast cancer, sponsored by Biokin Pharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07648914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648914.